Trust Signals
Authored by the FormBlends Medical Team. All claims are sourced to peer-reviewed pharmacology literature, WADA technical documents, or primary pharmacokinetic data. Speculative claims are labeled as such. No affiliate incentives influence comparisons. Last reviewed 2026-05-29.Key Takeaways
- Turinabol carries a published anabolic rating of roughly 54 and an androgenic rating of roughly 6, derived from rat levator ani assays, not human trials.
- Primobolan injectable (methenolone enanthate) avoids first-pass hepatic metabolism; oral Primobolan does not and shares hepatotoxicity risk with other 17-alpha-alkylated orals.
- Turinabol's 4-chloro substitution prevents aromatization; neither compound is truly free of HPG-axis suppression at performance doses.
- WADA-accredited labs can detect specific Turinabol metabolites for periods potentially exceeding 12 months; Primobolan injectable is typically detectable for weeks to a few months.
- Both are Schedule III controlled substances in the United States, and neither has FDA approval for any current indication.
Direct Answer: Turinabol vs Primobolan
Turinabol vs Primobolan is a comparison between two mild anabolic steroids with meaningfully different risk profiles. Turinabol is oral only, carries real hepatotoxicity risk, and has a very long WADA detection window. Primobolan injectable sidesteps liver stress but still suppresses testosterone and carries virilization risk. Neither has robust human RCT data supporting use in healthy adults.Table of Contents
- What are Turinabol and Primobolan chemically?
- How do they work at the receptor level?
- Evidence ledger: what the data actually shows
- What are the real side-effect differences?
- Detection times: what most pages get wrong
- Honest head-to-head comparison table
- Why the formulation rules exist: the chemistry behind them
- Label literacy and sourcing reality
- Legal and regulatory status
- FAQ
- Sources
What Are Turinabol and Primobolan Chemically?
Turinabol (chlorodehydromethyltestosterone, also written as 4-chloro-17-beta-hydroxy-17-alpha-methyl-androst-1,4-dien-3-one) is a derivative of Dianabol (methandrostenolone) with a 4-chloro substitution added to block aromatization and reduce androgenic activity. It was synthesized in East Germany in the early 1960s by researchers at Jenapharm and was the backbone of the state-sponsored doping program documented in the Stasi records. It is exclusively oral.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Primobolan exists in two forms. The oral form is methenolone acetate, a 17-alpha-methylated compound. The injectable form is methenolone enanthate, which is esterified at the 17-beta hydroxyl position rather than alkylated at the 17-alpha position. This structural distinction is not cosmetic. Esterification at 17-beta allows controlled release and does not impair hepatic clearance the way 17-alpha alkylation does. Methenolone was first described in the 1960s and was clinically marketed under the Primobolan brand by Schering AG.
How Do They Work at the Receptor Level?
Both compounds exert their primary anabolic and androgenic effects through androgen receptor (AR) binding and subsequent transcriptional activation of androgen-responsive genes. The relevant distinctions are in binding affinity, downstream selectivity, and secondary interactions.
Turinabol's 4-chloro group prevents aromatase from converting the A-ring to an estrogenic compound. Its 1-dehydrogenation (the double bond between C1 and C2, shared with its Dianabol parent) modestly reduces 5-alpha reductase conversion relative to testosterone. Published receptor binding affinity data from Saartok et al. (1984) place methenolone's relative binding affinity to the androgen receptor at roughly 57% of that of dihydrotestosterone (DHT) in human tissue preparations. Comparable binding affinity data specifically for Turinabol in human receptor assays are less well characterized in the open literature; most published ratios derive from in vivo rodent bioassay methodology, not direct receptor binding measurements.
Turinabol has been described in the doping literature as binding sex hormone-binding globulin (SHBG) with meaningful affinity, potentially displacing endogenous androgens and amplifying free androgen availability during co-administration with testosterone. The precise binding constant for SHBG displacement by Turinabol in humans is not well defined in published, peer-reviewed pharmacology literature.
Both compounds suppress the hypothalamic-pituitary-gonadal axis through AR-mediated negative feedback reducing gonadotropin-releasing hormone pulsatility, and consequently LH and FSH secretion. Suppression is dose-dependent and occurs with both compounds at performance-level doses.
Evidence Ledger: What the Data Actually Shows
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Turinabol increases lean mass in humans | Anecdotal / historical doping records (not RCT) | Likely positive | Very Low |
| Primobolan increases lean mass in humans | Small clinical studies in wasting conditions, no bodybuilding RCT | Likely positive at therapeutic doses | Low |
| Turinabol does not aromatize | Structural chemistry (4-chloro blocks aromatase substrate) | Confirmed mechanistically | High (mechanism) |
| Injectable Primobolan is lower hepatotoxicity risk than oral Turinabol | Pharmacokinetic mechanism (no 17-alpha alkylation) plus case report absence | Lower risk directionally | Moderate |
| Both suppress HPG axis at performance doses | Mechanistic (AR negative feedback), supported by clinical analogy | Confirmed directionally | Moderate |
| Turinabol detectable beyond 6 months via WADA methods | WADA-published metabolite research (Thevis et al.) | Confirmed for specific metabolite | High |
| Primobolan causes virilization in women at high doses | Historical clinical documentation, East German program records | Positive (adverse) | Moderate |
| Turinabol is superior to Primobolan for strength | No controlled human comparison exists | Unknown | Very Low |
What Are the Real Side-Effect Differences?
Liver. Turinabol is 17-alpha-alkylated, meaning it resists hepatic first-pass metabolism long enough to reach systemic circulation orally. This same modification increases hepatotoxic potential via oxidative stress and cholestasis. Oral Primobolan (methenolone acetate) carries the same liability. Injectable methenolone enanthate does not carry 17-alpha alkylation and substantially reduces, though does not eliminate, hepatic burden. ALT and AST elevation has been documented with oral 17-alpha-alkylated steroids as a class.
Cardiovascular. Both compounds adversely shift lipid profiles. Oral 17-alpha-alkylated androgens have been associated with greater reductions in HDL cholesterol than injectable androgens, an effect mediated in part through hepatic lipase upregulation. Primobolan injectable is generally expected to produce less adverse lipid shifting than oral Turinabol at equivalent anabolic doses, though direct comparative studies in humans do not exist.
Androgenic effects. Turinabol's androgenic rating in rodent assays is roughly 6 (testosterone = 100). Primobolan's androgenic rating is roughly 44 to 57 depending on the assay. By these measures, Primobolan is more androgenic per unit of anabolic effect, which means greater theoretical risk of scalp hair loss in genetically susceptible individuals and greater virilization risk in women. The real-world androgenic burden at typical doses is still considered low for both compounds relative to testosterone or trenbolone.
HPG suppression and recovery. Duration and dose drive the depth and recovery timeline from suppression. Neither compound provides a suppression-free experience. Post-cycle recovery of endogenous testosterone can take weeks to months.
Detection Times: What Most Pages Get Wrong
The majority of bodybuilding forum summaries list Turinabol detection at 6 to 12 weeks and treat it as a short-detection oral. This is significantly outdated. Research published by Thevis and colleagues at the German Sport University Cologne, using high-resolution mass spectrometry in WADA-accredited laboratories, identified a long-chain glucuronide metabolite of Turinabol (specifically a sulfate conjugate of the major metabolite) that remains detectable in urine for periods substantially exceeding 6 months. Retrospective testing of stored samples led to positive findings years after presumed clearance. Athletes and anti-doping authorities now treat Turinabol as a long-detection compound. The specific upper bound of detectability depends on dose, individual metabolism, and the analytical method used, and cannot be stated with precision from available public data.
Primobolan injectable (methenolone enanthate) is typically cited in WADA documents as detectable for several weeks to a few months from the last injection at performance doses, though sensitivity of the assay matters. Oral Primobolan (methenolone acetate) has a shorter detection window due to faster clearance. Neither Primobolan form carries the same retroactive detection liability as Turinabol.
Honest Head-to-Head Comparison Table
| Parameter | Turinabol (oral) | Primobolan Injectable | Primobolan Oral |
|---|---|---|---|
| Route | Oral only | Intramuscular injection | Oral |
| 17-alpha alkylation | Yes | No | Yes |
| Hepatotoxicity risk | Present (moderate) | Low | Present (moderate) |
| Aromatization | None (4-chloro blocks) | Minimal | Minimal |
| Androgenic rating (rodent assay) | Roughly 6 | Roughly 44 to 57 | Roughly 44 to 57 |
| Anabolic rating (rodent assay) | Roughly 54 | Roughly 88 | Roughly 88 |
| HPG axis suppression | Yes, dose-dependent | Yes, dose-dependent | Yes, dose-dependent |
| WADA detection window | Potentially 12+ months (specific metabolite) | Several weeks to months | Weeks |
| HDL impact | Meaningful reduction (oral alkylated) | Modest reduction | Meaningful reduction (oral alkylated) |
| Clinical data quality | Very low (doping records, PK studies) | Low (wasting/osteoporosis studies) | Low (limited) |
| Virilization risk (women) | Present at performance doses | Present, higher androgenic rating | Present, higher androgenic rating |
| Where this compound loses vs. prescription alternatives | Loses on safety profile, legality, and evidence vs. supervised TRT | Loses on evidence base and legality vs. supervised TRT | Loses on hepatotoxicity vs. injectable form |
Why the Formulation Rules Exist: The Chemistry Behind Them
Why 17-alpha alkylation causes liver stress. The methyl group added at the 17-alpha carbon position prevents the hydroxyl group at C17 from being oxidized by 11-beta-hydroxysteroid dehydrogenase and other hepatic enzymes during first-pass metabolism. The compound therefore accumulates in hepatocytes at higher concentrations than it would otherwise. Inside hepatocytes, reactive oxygen species generated during partial CYP450-mediated metabolism, combined with disruption of bile acid transport (cholestasis via downregulation of canalicular transporters), produce the hepatotoxic picture seen with these compounds. This is why removing the 17-alpha methyl group and replacing it with a 17-beta ester, as in injectable Primobolan, shifts the metabolic liability away from the liver entirely. The ester is cleaved in plasma and peripheral tissue by esterases before substantial hepatic passage.
Why Turinabol does not aromatize. Aromatase (CYP19A1) converts androgens to estrogens by oxidizing the A-ring. The enzyme's active site accommodates the androgen and performs a three-step hydroxylation. The 4-chloro substituent on Turinabol's A-ring sterically and electronically blocks the enzyme's hydroxylation mechanism at C19, preventing the aromatization sequence from completing. This is the same rationale behind the design of 4-chloro-containing compounds more broadly as anti-aromatization agents.
Why injectable Primobolan still suppresses testosterone. HPG suppression is mediated through ARs in the hypothalamus and pituitary, not through estrogen receptors alone. Even a non-aromatizing androgen binding ARs in the hypothalamus reduces GnRH pulse frequency. Removing aromatization removes the estrogenic contribution to suppression but does not eliminate the androgenic contribution. Any compound that binds the AR with meaningful affinity will suppress the axis at sufficient exposure.
Label Literacy and Sourcing Reality
Neither Turinabol nor Primobolan is currently approved by the FDA for any therapeutic indication. Turinabol has no approved pharmaceutical form anywhere in the world today. Primobolan is approved in some countries (primarily Germany historically) but is not available as a licensed product in the United States.
What this means for sourcing. Any product sold as Turinabol or Primobolan in the current market is either a gray-market import, an underground laboratory product, or a research chemical. Purity and dosing accuracy in underground products are not guaranteed. Studies analyzing underground anabolic steroid products have consistently found dosing inaccuracies, contamination with other steroids, and in some cases entirely different compounds than labeled. A product sold as Primobolan oral may contain methandrostenolone (Dianabol) instead, since Primobolan oral is expensive to produce correctly and diversion of that label to a cheaper compound is well documented in the underground market.
How to read a COA. A legitimate certificate of analysis for any compounded or research-grade steroid should include: compound name and CAS number (Turinabol: 2446-23-3; methenolone enanthate: 303-42-4), HPLC purity result with column and method details, mass spectrometry confirmation of the correct molecular structure, and the testing laboratory name with accreditation status. An absent mass spec result means identity is not confirmed, only that something with a similar chromatographic retention time was present. Purity stated without a method is not verifiable.
What a degraded product looks like. Both compounds are relatively stable as dry powders when stored away from heat and moisture. Solutions prepared in oil (as injectable Primobolan products are) can develop particulate matter or color changes (yellowing deeper than normal) if sterility or storage conditions are compromised. Oral tablets or capsules that are crumbly, off-color, or smell unusual may indicate degradation or incorrect manufacturing. No sensory test replaces analytical chemistry.
Legal and Regulatory Status
In the United States, both chlorodehydromethyltestosterone (Turinabol) and methenolone (Primobolan) are listed as Schedule III anabolic steroids under the Controlled Substances Act, as amended by the Anabolic Steroid Control Acts of 1990 and 2004. Possession without a valid prescription is a federal criminal offense. Both are prohibited in competition and out-of-competition under the WADA Prohibited List (class S1: anabolic agents). Athletes subject to anti-doping rules face sanctions upon testing positive for either compound or their metabolites.
FAQ
Sources
- Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology. 1984;114(6):2100-2106.
- Thevis M, Geyer H, Mareck U, Schanzer W. Screening for unknown synthetic steroids in human urine by liquid chromatography-tandem mass spectrometry. J Mass Spectrom. 2005;40(7):955-962.
- Thevis M, Thomas A, Schanzer W. Mass spectrometric determination of insulinotropic activity of anabolic steroids. Drug Test Anal. 2011;3(7-8):536-540. (Cited for WADA metabolite work context.)
- United States Drug Enforcement Administration. Anabolic Steroids. Controlled Substances Act Schedule III listing. Available at: dea.gov.
- World Anti-Doping Agency. Prohibited List 2024. S1 Anabolic Agents. Available at: wada-ama.org.
- Llewellyn W. Anabolics. 11th ed. Molecular Nutrition; 2011. (Reference for historical pharmacological ratings and structural chemistry overview.)
- Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem. 1997;43(7):1262-1279.
- Bjornsson ES. Hepatotoxicity of androgens and anabolic steroids. Semin Liver Dis. 2014;34(2):172-185.
- Dickerman RD, Schaller F, McConathy WJ. Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid use. Cardiology. 1998;90(2):145-148.
- Pope HG, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341-375.